Compare FMC Corp (FMC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs State Street SPDR S&P Biotech ETF — how do they compare? FMC Corp trades at $8.73 (market cap $1.39B), while State Street SPDR S&P Biotech ETF trades at $150.56 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 7.3× FMC Corp's market cap, and FMC Corp pays a 3.59% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FMC | XBI | |
|---|---|---|
Market Cap | $1.39B | $10.11B |
Volume | 4,145,979 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $30.63 | $169.55 |
52-Week Low | $8.44 | $104.99 |
Typical Hold Time | 68 Days | 37 Days |
Enterprise Value | $5.19B | — |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC Corporation (NYSE: FMC) trades at $8.695, down 4.35% today, reflecting ongoing challenges in the agricultural chemicals sector. The stock shows bearish technical signals with mixed earnings performance - beating Q1 and Q2 2026 estimates but missing Q4 2025. Fundamentally, the company faces significant headwinds with a net income margin of -84.83% and negative ROE of -91.47%, though valuation metrics like P/S of 0.34 and P/B of 0.85 suggest potential undervaluation. Recent developments include regulatory submissions for new herbicides in Brazil and a minority equity investment from Tessenderlo Group.
The investment outlook remains cautious despite analyst consensus pointing to 68% upside potential with a $14.60 price target. While aggressive deleveraging efforts and new product pipelines offer potential catalysts, substantial earnings losses, volatile cash flows, and high debt levels present significant risks. The agricultural sector's cyclical nature and pricing pressures require careful monitoring of the company's turnaround execution and market conditions.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
